View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPharmasimple 配当と自社株買い配当金 基準チェック /06Pharmasimple配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesBoard Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.お知らせ • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.分析記事 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).分析記事 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.分析記事 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.決済の安定と成長配当データの取得安定した配当: ALPHSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ALPHSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Pharmasimple 配当利回り対市場ALPHS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ALPHS)n/a市場下位25% (FR)2.0%市場トップ25% (FR)5.3%業界平均 (Specialty Retail)3.2%アナリスト予想 (ALPHS) (最長3年)n/a注目すべき配当: ALPHSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ALPHSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ALPHSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ALPHSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YFR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/02/09 22:34終値2024/02/09 00:00収益2021/06/30年間収益2020/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharmasimple SA これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Florent Thy-TineTPICAP Midcap
Board Change • Jun 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Didier Petre was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Director Alexandre Plissart was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 15Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: €30.0m (down 35% from FY 2020). Net loss: €9.10m (loss widened 499% from FY 2020). Revenue was in line with analyst estimates.
お知らせ • Sep 01Pharmasimple SA announced that it expects to receive €10 million in funding from Alpha Blue Ocean IncPharmasimple SA announced a private placement of bonds convertible into shares with a maximum amount of €10 million in a round of funding on August 31, 2021. The transaction will include participation from Alpha Blue Ocean. The convertible bonds with a nominal value of 5,000 euros will be subscribed in increments of 0.5 million euros, which means that a maximum of 20 tranches, representing a total of 2,000 convertible bonds, may be subscribed until August 27, 2026.
分析記事 • Jul 31One Analyst Just Shaved Their Pharmasimple SA (EPA:ALPHS) Forecasts DramaticallyThe analyst covering Pharmasimple SA ( EPA:ALPHS ) delivered a dose of negativity to shareholders today, by making a...
Major Estimate Revision • Jul 23Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -€0.43 to -€0.60 per share. Revenue forecast of €36.7m unchanged since last update. Online Retail industry in France expected to see average net income growth of 5.1% next year. Consensus price target down from €11.00 to €9.80. Share price was steady at €6.40 over the past week.
Breakeven Date Change • May 26No longer forecast to breakevenThe analyst covering Pharmasimple no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €1.10m in 2021. New forecast suggests the company will make a loss of €500.0k in 2022.
Price Target Changed • May 26Price target decreased to €11.00Down from €14.30, the current price target is provided by 1 analyst. New target price is 44% above last closing price of €7.62. Stock is down 39% over the past year.
Reported Earnings • Apr 16Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €45.2m (up 61% from FY 2019). Net loss: €1.50m (loss narrowed 46% from FY 2019).
分析記事 • Apr 12Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Dec 28New 90-day high: €10.35The company is up 7.0% from its price of €9.70 on 29 September 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 52% over the same period.
分析記事 • Dec 27Analysts Expect Pharmasimple SA (EPA:ALPHS) To Breakeven SoonPharmasimple SA ( EPA:ALPHS ) is possibly approaching a major achievement in its business, so we would like to shine...
Is New 90 Day High Low • Nov 17New 90-day low: €8.76The company is down 9.0% from its price of €9.60 on 19 August 2020. The French market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 27% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: €8.86The company is down 9.0% from its price of €9.78 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 20% over the same period.